Equities analysts expect DexCom, Inc. (NASDAQ:DXCM) to report sales of $217.73 million for the current quarter, Zacks reports. Three analysts have made estimates for DexCom’s earnings, with estimates ranging from $217.50 million to $217.98 million. DexCom posted sales of $171.20 million during the same quarter last year, which suggests a positive year-over-year growth rate of 27.2%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that DexCom will report full-year sales of $217.73 million for the current fiscal year, with estimates ranging from $715.00 million to $725.00 million. For the next fiscal year, analysts forecast that the company will post sales of $838.25 million per share, with estimates ranging from $833.80 million to $847.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for DexCom.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%.

A number of analysts recently issued reports on DXCM shares. TheStreet cut DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Wedbush restated a “buy” rating and set a $76.00 target price on shares of DexCom in a report on Wednesday, October 4th. Raymond James Financial lowered DexCom from an “outperform” rating to a “mkt perform” rating in a report on Friday, September 29th. Northland Securities initiated coverage on DexCom in a report on Tuesday, September 26th. They set an “outperform” rating and a $85.00 target price on the stock. Finally, Canaccord Genuity restated a “buy” rating and set a $69.00 target price (down from $90.00) on shares of DexCom in a report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $68.50.

DexCom (NASDAQ DXCM) traded down $0.34 on Tuesday, reaching $56.41. The company had a trading volume of 1,017,600 shares, compared to its average volume of 2,206,590. The firm has a market capitalization of $4,900.00, a PE ratio of -98.96 and a beta of 0.31. DexCom has a 52-week low of $42.62 and a 52-week high of $86.74. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

In related news, EVP Andrew K. Balo sold 3,245 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $61.23, for a total transaction of $198,691.35. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $44.82, for a total value of $73,280.70. Following the transaction, the executive vice president now owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders sold 38,140 shares of company stock worth $2,158,576 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. boosted its holdings in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares in the last quarter. Zions Bancorporation boosted its holdings in DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares in the last quarter. Toronto Dominion Bank boosted its holdings in shares of DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after acquiring an additional 2,608 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after acquiring an additional 354 shares in the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in shares of DexCom in the 2nd quarter worth approximately $249,000.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect DexCom, Inc. (DXCM) Will Announce Quarterly Sales of $217.73 Million” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/16/zacks-brokerages-expect-dexcom-inc-dxcm-will-announce-quarterly-sales-of-217-73-million.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.